ImmunityBio (IBRX) stock jumps as the FDA agrees to review the company's bid to expand the label for bladder cancer therapy ...

Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary diseaseFDA ...

IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales ...

ImmunityBio Inc. IBRX presented two indirect treatment comparison analyses, highlighting efficacy and safety outcomes for ...

Photocure ASA reported new real-world data presented at the American Urological Association 2026 congress showing that Blue Light Cystoscopy significantly improves early detection of carcinoma in situ ...

The ongoing LEGEND phase 2 trial is testing a novel, investigational non-viral, intravesical gene therapy (EG-70) in patients with BCG-unresponsive NMIBC to elicit a local innate and adaptive immune ...

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced results ...

Why do adolescents and young adults with cancer require special treatment considerations, and how can proton therapy help ...

An evidence gap persists in BCG-unresponsive NMIBC because pivotal approvals rely on single-arm studies, making indirect ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the ...

Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin ...

Ferring Pharmaceuticals today announced a new real-world case series demonstrating that re-induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) resulted in complete responses (CR) in ...